140 related articles for article (PubMed ID: 29778506)
1. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
von Gruenigen VE; Huang HQ; Cella D; Zevon M; LaChance JA; Walker JL; Salani R; Modesitt SC; Morris RT; Bradley WH; Boente MP; Wenzel L
Gynecol Oncol; 2018 Jul; 150(1):119-126. PubMed ID: 29778506
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
Wenzel L; Huang HQ; Cella D; McKinney CO; Zevon MA; LaChance JA; Walker JL; Salani R; Modesitt SC; Morris RT; Bradley WH; Boente MP; von Gruenigen VE
Gynecol Oncol; 2021 Nov; 163(2):392-397. PubMed ID: 34548162
[TBL] [Abstract][Full Text] [Related]
3. Caring for women with ovarian cancer in the last year of life: a longitudinal study of caregiver quality of life, distress and unmet needs.
Butow PN; Price MA; Bell ML; Webb PM; deFazio A; ; ; Friedlander M
Gynecol Oncol; 2014 Mar; 132(3):690-7. PubMed ID: 24423880
[TBL] [Abstract][Full Text] [Related]
4. Further content validation of the 18-item NCCN/FACT Ovarian Symptom Index and its Disease Related Symptom-Physical (DRS-P) subscale for use in advanced ovarian cancer clinical trials.
Shaunfield S; Jensen S; Fisher AP; Webster K; Shahabi S; Ganguli A; Cella D
Health Qual Life Outcomes; 2019 Dec; 17(1):185. PubMed ID: 31856850
[TBL] [Abstract][Full Text] [Related]
5. Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.
Joly F; Ahmed-Lecheheb D; Kalbacher E; Heutte N; Clarisse B; Grellard JM; Gernier F; Berton-Rigaud D; Tredan O; Fabbro M; Savoye AM; Kurtz JE; Alexandre J; Follana P; Delecroix V; Dohollou N; Roemer-Becuwe C; De Rauglaudre G; Lortholary A; Prulhiere K; Lesoin A; Zannetti A; N'Guyen S; Trager-Maury S; Chauvenet L; Abadie Lacourtoisie S; Gompel A; Lhommé C; Floquet A; Pautier P
Ann Oncol; 2019 May; 30(5):845-852. PubMed ID: 30851097
[TBL] [Abstract][Full Text] [Related]
6. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
King MT; Stockler MR; O'Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML;
Qual Life Res; 2018 Jan; 27(1):59-74. PubMed ID: 29248998
[TBL] [Abstract][Full Text] [Related]
7. OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors.
Webber K; Carolus E; Mileshkin L; Sommeijer D; McAlpine J; Bladgen S; Coleman RL; Herzog TJ; Sehouli J; Nasser S; Inci G; Friedlander M
Gynecol Oncol; 2019 Oct; 155(1):126-134. PubMed ID: 31416612
[TBL] [Abstract][Full Text] [Related]
8. Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.
Phippen NT; Secord AA; Wolf S; Samsa G; Davidson B; Abernethy AP; Cella D; Havrilesky LJ; Burger RA; Monk BJ; Leath CA
Gynecol Oncol; 2017 Oct; 147(1):98-103. PubMed ID: 28743369
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
10. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato FT; Joly F; O'Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M;
Oncologist; 2017 Sep; 22(9):1117-1124. PubMed ID: 28596446
[TBL] [Abstract][Full Text] [Related]
11. Content validity of the NCCN-FACT ovarian symptom index-18 (NFOSI-18).
Jensen SE; Kaiser K; Lacson L; Schink J; Cella D
Gynecol Oncol; 2015 Feb; 136(2):317-22. PubMed ID: 25499602
[TBL] [Abstract][Full Text] [Related]
12. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT;
Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219
[TBL] [Abstract][Full Text] [Related]
13. A new index of priority symptoms in advanced ovarian cancer.
Jensen SE; Rosenbloom SK; Beaumont JL; Abernethy A; Jacobsen PB; Syrjala K; Cella D
Gynecol Oncol; 2011 Feb; 120(2):214-9. PubMed ID: 21075440
[TBL] [Abstract][Full Text] [Related]
14. Reliability, validity and important difference estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18).
Trigg A; Kelly M; Iadeluca L; Chang J; Moreno-Koehler A; Yaworsky A; Krohe M; Rider A; Cappelleri JC; Cella D; Cocks K
Future Oncol; 2021 Oct; 17(30):3951-3964. PubMed ID: 34287020
[TBL] [Abstract][Full Text] [Related]
15. Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259).
Donovan HS; Sereika SM; Wenzel LB; Edwards RP; Knapp JE; Hughes SH; Roberge MC; Thomas TH; Klein SJ; Spring MB; Nolte S; Landrum LM; Casey AC; Mutch DG; DeBernardo RL; Muller CY; Sullivan SA; Ward SE
J Clin Oncol; 2022 May; 40(13):1464-1473. PubMed ID: 35130043
[TBL] [Abstract][Full Text] [Related]
16. Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients.
Brown AJ; Sun CC; Urbauer DL; Bodurka DC; Thaker PH; Ramondetta LM
Gynecol Oncol; 2015 Aug; 138(2):388-93. PubMed ID: 25988961
[TBL] [Abstract][Full Text] [Related]
17. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML
Int J Gynecol Cancer; 2014 Jun; 24(5):865-73. PubMed ID: 24844220
[TBL] [Abstract][Full Text] [Related]
18. Determinants of quality of life in ovarian cancer survivors: a pilot study.
Teng FF; Kalloger SE; Brotto L; McAlpine JN
J Obstet Gynaecol Can; 2014 Aug; 36(8):708-715. PubMed ID: 25222166
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum.
Frey MK; Ellis AE; Koontz LM; Shyne S; Klingenberg B; Fields JC; Chern JY; Blank SV
Gynecol Oncol; 2017 Aug; 146(2):386-391. PubMed ID: 28602549
[TBL] [Abstract][Full Text] [Related]
20. "Lower abdominal pains, as if I was being squeezed…in a clamp": A Qualitative Analysis of Symptoms, Patient-Perceived Side Effects and Impacts of Ovarian Cancer.
Martin ML; Halling K; Eek D; Reaney M
Patient; 2020 Apr; 13(2):189-200. PubMed ID: 31691205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
